List of Excipients in Branded Drug MORPHINE SULFATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hikma Pharmaceuticals USA Inc	MORPHINE SULFATE	morphine sulfate	0054-0235	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	MORPHINE SULFATE	morphine sulfate	0054-0235	SILICON DIOXIDE
Hikma Pharmaceuticals USA Inc	MORPHINE SULFATE	morphine sulfate	0054-0235	STARCH, CORN
Hikma Pharmaceuticals USA Inc	MORPHINE SULFATE	morphine sulfate	0054-0235	STEARIC ACID

Generic Drugs Containing MORPHINE SULFATE

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals of New York LLC	morphine sulfate	0115-1277	ALCOHOL
Amneal Pharmaceuticals of New York LLC	morphine sulfate	0115-1277	AMMONIA
Amneal Pharmaceuticals of New York LLC	morphine sulfate	0115-1277	BUTYL ALCOHOL
Amneal Pharmaceuticals of New York LLC	morphine sulfate	0115-1277	DIETHYL PHTHALATE

What are the Most Frequently-Used Excipients in MORPHINE SULFATE?

# Of NDCs	Excipient
4	ALCOHOL
1	ALUMINUM OXIDE
3	AMMONIA
11	ANHYDROUS CITRIC ACID

Excipient Strategy and Commercial Opportunities for Morphine Sulfate

Last updated: February 25, 2026

What are the key excipient considerations for formulations of morphine sulfate?

Morphine sulfate is administered through various routes, including oral, injectable, and transdermal forms. The choice of excipients depends on the administration route, desired release profile, stability, and bioavailability.

How do excipient choices impact morphine sulfate formulations?

Oral formulations: Use of diluents, binders, disintegrants, and flavoring agents. Common agents include microcrystalline cellulose, starch, magnesium stearate, and sucralose. These enhance tablet integrity, stability, and palatability.

Injectable formulations: Use of solvents like sterile water, bacteriostatic water, or saline. Excipients such as sodium bisulfite serve as preservatives, while stabilizers like EDTA prevent degradation.

Transdermal patches: Use of adhesives, permeability enhancers (e.g., oleic acid, isopropyl myristate), and surfactants to facilitate drug permeation. These components influence drug release rate and adhesion quality.

Key considerations: Compatibility with active ingredient, osmolarity, pH stability, inertness, and minimal toxicity.

What commercial opportunities exist through excipient innovation?

Enhanced bioavailability: Developing excipient systems that improve absorption, such as cyclodextrins or lipid-based excipients, can lead to formulations with quicker onset and higher efficacy.

Extended-release formulations: Utilizing excipients like matrix-forming polymers (e.g., hydroxypropyl methylcellulose) allows for sustained drug release, reducing dosing frequency and improving patient compliance.

Alternative routes: Formulations employing novel excipients for non-invasive delivery (e.g., nasal sprays, buccal patches) open markets for patients with swallowing difficulties or requiring rapid analgesia.

Stability improvement: Excipients that increase shelf-life under various storage conditions, such as antioxidants or moisture scavengers, extend product viability and reduce logistics costs.

Customization and niche products: Combining excipients to address specific patient populations (e.g., pediatric or geriatric), offering tailored doses or reduced side effects.

What are current trends and regulatory considerations?

Regulatory agencies emphasize excipient safety. The FDA and EMA require detailed excipient profiles for new formulations, especially for routes outside traditional use. The trend toward natural or plant-derived excipients is increasing, aligning with consumer preferences.

Innovation in excipient technology faces challenges such as patent expiration of key excipients, leading to potential generic competition. Developing proprietary excipient systems or delivery platforms can create sustainable competitive advantages.

What financial implications do excipient strategies entail?

Investment in research yields potential for premium pricing, particularly for formulations with improved bioavailability or reduced dosage frequency. However, cost considerations include excipient sourcing, regulatory approvals, and quality control.

Market data indicates the global opioids market, valued at approximately USD 9 billion (2021), includes significant margins for formulations with differentiated features. Innovation in excipients can enhance product value, market share, and reduce manufacturing costs through process simplifications.

What partnership opportunities are relevant?

Contract manufacturing organizations (CMOs) specializing in complex formulations can facilitate development. Collaboration with excipient suppliers offers early access to novel materials, regulatory support, and cost efficiencies.

What are the key risks?

Regulatory restrictions on opioids, including excipient safety concerns in vulnerable populations, could delay approvals or limit formulations. Patent challenges on excipient technology may weaken exclusivity. Supply chain disruptions of critical excipients could impact manufacturing.

Key Takeaways

• Excipient selection for morphine sulfate varies with formulation route and desired release profile.
• Innovation in excipient technology can improve bioavailability, stability, and patient compliance.
• Market opportunities include sustained-release, novel delivery routes, and niche patient-specific formulations.
• Regulatory oversight emphasizes safety and natural excipient trends.
• Partnerships with CMOs and excipient suppliers support development efforts.

FAQs

1. What are the common excipients in morphine sulfate injectable formulations?
   Sodium bisulfite as a preservative, sterile water or saline as solvents, and stabilizers like EDTA.

2. Can excipients influence the efficacy of morphine sulfate?
   Yes. Excipients affect drug stability, absorption, and release profile, impacting overall efficacy.

3. Are there patented excipient technologies for morphine formulations?
   Proprietary excipient systems exist, particularly for sustained-release or novel delivery mechanisms.

4. What challenges exist in developing excipient-based formulations?
   Ensuring compatibility, regulatory approval, and supply chain stability.

5. How does excipient choice affect regulatory approval?
   Regulators require detailed safety data and justification for excipient use, especially in non-traditional routes.

---

References

[1] Food and Drug Administration. (2022). Guidance for Industry: Nonclinical Testing of Orally Inhaled Nicotine and Tobacco Products. FDA.
[2] European Medicines Agency. (2022). Guideline on the specification for pharmaceutical substances. EMA.
[3] Williams, R. O., & Roberts, D. (2021). Advances in drug delivery systems for opioids. International Journal of Pharmaceutics, 590, 119929.
[4] MarketWatch. (2022). Opioids Market Size, Trends, and Forecasts.
[5] US Patent and Trademark Office. (2022). Patent filing on sustained-release excipient systems.